These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19072222)

  • 1. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
    Katsara M; Deraos G; Tselios T; Matsoukas MT; Friligou I; Matsoukas J; Apostolopoulos V
    J Med Chem; 2009 Jan; 52(1):214-8. PubMed ID: 19072222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice.
    Katsara M; Deraos G; Tselios T; Matsoukas J; Apostolopoulos V
    J Med Chem; 2008 Jul; 51(13):3971-8. PubMed ID: 18563891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses of linear and cyclic PLP139-151 mutant peptides in SJL/J mice: peptides in their free state versus mannan conjugation.
    Katsara M; Deraos S; Tselios TV; Pietersz G; Matsoukas J; Apostolopoulos V
    Immunotherapy; 2014; 6(6):709-24. PubMed ID: 25186603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered peptide ligands of myelin basic protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in mice.
    Katsara M; Yuriev E; Ramsland PA; Tselios T; Deraos G; Lourbopoulos A; Grigoriadis N; Matsoukas J; Apostolopoulos V
    Immunology; 2009 Dec; 128(4):521-33. PubMed ID: 19930042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses.
    Katsara M; Yuriev E; Ramsland PA; Deraos G; Tselios T; Matsoukas J; Apostolopoulos V
    J Neuroimmunol; 2008 Aug; 200(1-2):77-89. PubMed ID: 18675465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker.
    Tselios TV; Lamari FN; Karathanasopoulou I; Katsara M; Apostolopoulos V; Pietersz GA; Matsoukas JM; Karamanos NK
    Anal Biochem; 2005 Dec; 347(1):121-8. PubMed ID: 16246290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
    Deraos G; Rodi M; Kalbacher H; Chatzantoni K; Karagiannis F; Synodinos L; Plotas P; Papalois A; Dimisianos N; Papathanasopoulos P; Gatos D; Tselios T; Apostolopoulos V; Mouzaki A; Matsoukas J
    Eur J Med Chem; 2015 Aug; 101():13-23. PubMed ID: 26112377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease.
    Deraos G; Chatzantoni K; Matsoukas MT; Tselios T; Deraos S; Katsara M; Papathanasopoulos P; Vynios D; Apostolopoulos V; Mouzaki A; Matsoukas J
    J Med Chem; 2008 Dec; 51(24):7834-42. PubMed ID: 19053745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
    Darlington C
    Curr Opin Mol Ther; 2007 Aug; 9(4):398-402. PubMed ID: 17694453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
    Bielekova B; Goodwin B; Richert N; Cortese I; Kondo T; Afshar G; Gran B; Eaton J; Antel J; Frank JA; McFarland HF; Martin R
    Nat Med; 2000 Oct; 6(10):1167-75. PubMed ID: 11017150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic citrullinated MBP
    Apostolopoulos V; Deraos G; Matsoukas MT; Day S; Stojanovska L; Tselios T; Androutsou ME; Matsoukas J
    Bioorg Med Chem; 2017 Jan; 25(2):528-538. PubMed ID: 27908754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
    Matsoukas J; Apostolopoulos V; Kalbacher H; Papini AM; Tselios T; Chatzantoni K; Biagioli T; Lolli F; Deraos S; Papathanassopoulos P; Troganis A; Mantzourani E; Mavromoustakos T; Mouzaki A
    J Med Chem; 2005 Mar; 48(5):1470-80. PubMed ID: 15743189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific immunotherapy: one size does not fit all.
    Genain CP; Zamvil SS
    Nat Med; 2000 Oct; 6(10):1098-100. PubMed ID: 11017135
    [No Abstract]   [Full Text] [Related]  

  • 14. A Cyclic Altered Peptide Analogue Based on Myelin Basic Protein 87-99 Provides Lasting Prophylactic and Therapeutic Protection Against Acute Experimental Autoimmune Encephalomyelitis.
    Emmanouil M; Tseveleki V; Triantafyllakou I; Nteli A; Tselios T; Probert L
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response.
    Mantzourani ED; Platts JA; Brancale A; Mavromoustakos TM; Tselios TV
    J Mol Graph Model; 2007 Sep; 26(2):471-81. PubMed ID: 17392002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99.
    Mantzourani ED; Tselios TV; Grdadolnik SG; Brancale A; Platts JA; Matsoukas JM; Mavromoustakos TM
    J Mol Graph Model; 2006 Sep; 25(1):17-29. PubMed ID: 16310386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degeneracy, as opposed to specificity, in immunotherapy.
    Hafler DA
    J Clin Invest; 2002 Mar; 109(5):581-4. PubMed ID: 11877465
    [No Abstract]   [Full Text] [Related]  

  • 18. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.
    Trabattoni D; Saresella M; Pacei M; Marventano I; Mendozzi L; Rovaris M; Caputo D; Borelli M; Clerici M
    J Immunol; 2009 Oct; 183(8):4984-93. PubMed ID: 19794071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against a class II HLA-peptide complex raised by active immunization of mice with antigen mimicking peptides.
    Dam-Tuxen R; Riise E
    Scand J Immunol; 2009 Aug; 70(2):93-100. PubMed ID: 19630914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putative bioactive conformations of amide linked cyclic myelin basic protein peptide analogues associated with experimental autoimmune encephalomyelitis.
    Spyranti Z; Dalkas GA; Spyroulias GA; Mantzourani ED; Mavromoustakos T; Friligou I; Matsoukas JM; Tselios TV
    J Med Chem; 2007 Nov; 50(24):6039-47. PubMed ID: 17979262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.